Physician profile
Lydia Capps
NPI 1922666106
$5,600.38
in general payments reported to CMS, 2019-2025
35 companies · $32.42 in 2025
The $32.42 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,992 · 2022: $2,250 · 2023: $1,284 · 2024: $42.04 · 2025: $32.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,358.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,196.10 | 2021-2025 | |
| Novo Nordisk INC | $1,164.60 | 2021-2023 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $529.43 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $347.61 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $336.89 | 2021-2023 | Farxiga |
| Esperion Therapeutics, INC. | $272.35 | 2021-2022 | |
| Astellas Pharma US INC | $196.78 | 2021-2022 | |
| Amgen INC. | $158.94 | 2021-2023 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $131.63 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $127.59 | 2022 | |
| Merck Sharp & Dohme LLC | $118.03 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.84 | 2021-2023 | Jardiance |
| Mylan Specialty L.P. | $105.99 | 2021-2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $90.33 | 2021-2023 | |
| Pfizer INC. | $61.29 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $57.28 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $56.52 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $49.79 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $48.89 | 2023 | Crysvita |
| Biogen, INC. | $46.96 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $43.27 | 2021 | |
| Sanofi Pasteur INC. | $34.57 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.19 | 2022-2023 | |
| Daiichi Sankyo INC. | $31.58 | 2021 | |
| Ibsa Pharma INC. | $30.91 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.33 | 2023 | Xifaxan |
| Impel Pharmaceuticals INC. | $29.55 | 2022-2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $26.97 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.79 | 2022 | |
| Ironshore Pharmaceuticals INC. | $21.88 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $19.62 | 2021 | |
| Dexcom, INC. | $17.21 | 2021 | |
| Horizon Therapeutics Plc | $16.21 | 2022 | |
| Glaxosmithkline, LLC. | $13.86 | 2025 | Bexsero, Shingrix, Arexvy |
| Corcept Therapeutics | $13.60 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Capps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.